D-0502 not checked

InventisBio Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
4 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“* Dosage form: Tablet * Administration route: Oral, once a day”In the company’s words, NCT06954961 on ClinicalTrials.gov
Tested for
Breast Cancer
Main trialPhase 3
“This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.”In the company’s words, NCT06954961 on ClinicalTrials.gov

Other drugs for Breast Cancer

All 396 drugs for Breast Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Nov 2026 A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
Phase 1Completed 23 Dec 2021 Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects
Phase 1Completed 2 Aug 2022 Study in Healthy Adult Female Subjects
Phase 1Completed 18 Oct 2023 A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow D-0502

Following is part of Solo: you see every change to D-0502 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in